Cargando…

Bleeding complications in patients with squamous cell carcinoma of the head and neck

Hemorrhage in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) may be attributed to chemotherapy and local tumor irradiation. Evidence of the relationship between hemorrhage in R/M HNSCC and targeted therapies, including epidermal growth factor receptor (EGFR) and vasc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bergamini, Cristiana, Ferris, Robert L., Xie, Jing, Mariani, Gabriella, Ali, Muzammil, Holmes, William C., Harrington, Kevin, Psyrri, Amanda, Cavalieri, Stefano, Licitra, Lisa
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2021
Materias:	Clinical Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8453784/ https://www.ncbi.nlm.nih.gov/pubmed/34117666 http://dx.doi.org/10.1002/hed.26772

Ejemplares similares

Immunotherapy in head and neck squamous cell carcinoma and rare head and neck malignancies
por: Cavalieri, Stefano, et al.
Publicado: (2021)

Head and Neck Cancer
por: Psyrri, Amanda, et al.
Publicado: (2009)

Treatment of HER2+ metastatic salivary ductal carcinoma in a pregnant woman: a case report
por: Bergamini, Cristiana, et al.
Publicado: (2019)

Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Argiris, Athanassios, et al.
Publicado: (2017)

The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches
por: Economopoulou, Panagiota, et al.
Publicado: (2017)

De-Escalating Strategies in HPV-Associated Head and Neck Squamous Cell Carcinoma
por: Economopoulou, Panagiota, et al.
Publicado: (2021)

Activity of platinum and cetuximab in cutaneous squamous cell cancer not amenable to curative treatment
por: Galbiati, Donata, et al.
Publicado: (2019)

929TiP HERODOTUS: Head and neck cancers international COVID-19 collaboration: An international registry on head and neck cancer with COVID-19
por: Psyrri, A., et al.
Publicado: (2021)

The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports
por: Colombo, Elena, et al.
Publicado: (2023)

Diagnostic Tumor Markers in Head and Neck Squamous Cell Carcinoma (HNSCC) in the Clinical Setting
por: Economopoulou, Panagiota, et al.
Publicado: (2019)

Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age
por: Saba, Nabil F., et al.
Publicado: (2019)

Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma
por: Bossi, Paolo, et al.
Publicado: (2016)

Mining of Self-Organizing Map Gene-Expression Portraits Reveals Prognostic Stratification of HPV-Positive Head and Neck Squamous Cell Carcinoma
por: Locati, Laura D., et al.
Publicado: (2019)

Inflammatory Arthritis Induced by Pembrolizumab in a Patient With Head and Neck Squamous Cell Carcinoma
por: Spathas, Nikolaos, et al.
Publicado: (2018)

Editorial: Women in head and neck cancer 2021
por: Economopoulou, Panagiota, et al.
Publicado: (2022)

Immunotherapy for Head and Neck Squamous Cell Carcinoma
por: Moskovitz, Jessica, et al.
Publicado: (2018)

Tumor Microenvironment and Immunotherapy Response in Head and Neck Cancer
por: Economopoulou, Panagiota, et al.
Publicado: (2020)

The Role of B Cells in Head and Neck Cancer
por: Gavrielatou, Niki, et al.
Publicado: (2021)

Editorial: Immunology and Immunotherapy of Head and Neck Cancer
por: Gavrielatou, Niki, et al.
Publicado: (2021)

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)
por: Cohen, Ezra E. W., et al.
Publicado: (2019)

Impact of tumor HPV status on outcome in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without cetuximab: retrospective analysis of the phase III EXTREME trial
por: Vermorken, J. B., et al.
Publicado: (2014)

Editorial: Women in head and neck cancer, volume II: 2022
por: Economopoulou, Panagiota, et al.
Publicado: (2023)

Tipifarnib in Head and Neck Squamous Cell Carcinoma With HRAS Mutations
por: Ho, Alan L., et al.
Publicado: (2021)

Special Issue about Head and Neck Cancers: HPV Positive Cancers
por: Economopoulou, Panagiota, et al.
Publicado: (2020)

Complete Response to Nivolumab in Recurrent/Metastatic HPV-Positive Head and Neck Squamous Cell Carcinoma Patient After Progressive Multifocal Leukoencephalopathy: A Case Report
por: Locati, Laura Deborah, et al.
Publicado: (2022)

Markers of Epithelial to Mesenchymal Transition in Association with Survival in Head and Neck Squamous Cell Carcinoma (HNSCC)
por: Pectasides, Eirini, et al.
Publicado: (2014)

Abiraterone Acetate in Patients With Castration-Resistant, Androgen Receptor–Expressing Salivary Gland Cancer: A Phase II Trial
por: Locati, Laura D., et al.
Publicado: (2021)

The DNA damage response network in the treatment of head and neck squamous cell carcinoma
por: Psyrri, A., et al.
Publicado: (2021)

Editorial: Advances in the Systemic Therapy and Combined Modality Approaches for Head and Neck Cancer
por: Argiris, Athanassios, et al.
Publicado: (2019)

Treating Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck Unsuitable to Receive Cisplatin-Based Therapy
por: Porceddu, Sandro V., et al.
Publicado: (2020)

Are Fusion Transcripts in Relapsed/Metastatic Head and Neck Cancer Patients Predictive of Response to Anti-EGFR Therapies?
por: Bossi, Paolo, et al.
Publicado: (2017)

Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy
por: Machiels, Jean-Pascal H, et al.
Publicado: (2014)

Direct comparison of size-dependent versus EpCAM-dependent CTC enrichment at the gene expression and DNA methylation level in head and neck squamous cell carcinoma
por: Zavridou, Martha, et al.
Publicado: (2020)

The Evolving Role of Taxanes in Combination With Cetuximab for the Treatment of Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Evidence, Advantages, and Future Directions
por: Guigay, Joël, et al.
Publicado: (2019)

Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial
por: Haddad, Robert, et al.
Publicado: (2019)

HER2 status in recurrent/metastatic androgen receptor overexpressing salivary gland carcinoma patients
por: Cavalieri, Stefano, et al.
Publicado: (2023)

Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle
por: Ferris, Robert L, et al.
Publicado: (2015)

Tumor Biomarkers for the Prediction of Distant Metastasis in Head and Neck Squamous Cell Carcinoma
por: Alfieri, Salvatore, et al.
Publicado: (2020)

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study
por: Harrington, Kevin J., et al.
Publicado: (2023)

Strategies to promote translational research within the European Organisation for Research and Treatment of Cancer (EORTC) Head and Neck Cancer Group: a report from the Translational Research Subcommittee
por: Psyrri, A., et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_cr3798rooen0khvot0uv4pul70